BEAM Beam Therapeutics Inc.companySEC Filings & Insider Trading Activity 2026
Latest Beam Therapeutics Inc. (BEAM) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 24, 2026, a 10-Q quarterly report filed on November 4, 2025, an 8-K current report filed on March 5, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Beam Therapeutics Inc. (BEAM) (SEC CIK 1745999), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Fully integrated precision genetic medicines platform based on proprietary base editing gene editing technology without DNA double-strand breaks
- • New products/segments: Announced BEAM-304 for phenylketonuria (PKU) and advancing in vivo LNP liver-targeted base editors BEAM-302 (AATD) and BEAM-301 (GSDIa)
Risk Factors
- • Cybersecurity risk oversight by Audit Committee with quarterly management updates and immediate alerts on significant incidents
- • Dependence on VP, IS with 25 years experience and CISSP and CISA certifications for cybersecurity program leadership
Management Discussion & Analysis
- • Revenue $139.7M in 2025 vs $63.5M in 2024 and $377.7M in 2023, primarily from license and collaboration agreements
- • Net loss $80.0M in 2025 vs $376.7M loss in 2024 and $132.5M loss in 2023, accumulated deficit $1.6B at 2025 year-end
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New regulatory risk: FDA orphan drug and regenerative medicine advanced therapy designations granted for BEAM-302 in 2025, triggering expanded clinical trial and regulatory requirements
- • Updated clinical risk: BEACON trial interim data on BEAM-101 showed sustained mean total Hb increase to 15.6 g/dL at month six, with no Grade 3+ adverse events reported
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 1.02: Termination of a Material Definitive Agreement
- • Bio Palette License Agreement terminated March 2, 2026 due to Bio Palette's planned dissolution — no future payments owed by either party
- • Continuity secured: Kobe University standby license (signed Feb 9, 2026) activated, preserving BEAM's exclusive base editing patent rights
Item 2.02: Results of Operations and Financial Condition
- • Q4 2025 earnings reported Feb 24, 2026 — full results in Exhibit 99.1 press release
- • BEAM is a clinical-stage gene editing company; revenue/burn rate and cash runway are key investor metrics to track in the release
Item 1.01: Entry into a Material Definitive Agreement
- • $500M senior secured term loan from Sixth Street; only $100M drawn at close, remaining $400M milestone-gated on FDA BLA acceptance, approval, and risto-cel revenue targets
- • Interest rate: 3-month SOFR + 6.50% (1.00% floor), interest-only quarterly payments with full principal bullet due Feb 2033
Annual Reports Archive10-K
AI-powered analysis of Beam Therapeutics Inc. (BEAM) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Beam Therapeutics Inc. (BEAM) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Beam Therapeutics Inc. (BEAM) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $60.9M | $377.7M | $63.5M | $139.7M |
| Operating Income | -$338.5M | -$176.5M | -$415.6M | -$383.7M |
| Net Income | -$289.1M | -$132.5M | -$376.7M | -$80.0M |
| Op. Margin | -555.6% | -46.7% | -654.3% | -274.6% |
| Net Margin | -474.5% | -35.1% | -593.1% | -57.2% |
| Balance Sheet | ||||
| Total Assets | $1.3B | $1.5B | $1.1B | $1.5B |
| Equity | $733.5M | $981.3M | $733.5M | $1.2B |
| ROE | -39.4% | -13.5% | -51.4% | -6.5% |
Source: XBRL financial data from Beam Therapeutics Inc. (BEAM) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 5, 2026 | — | Analysis | — |
8-K | Feb 24, 2026 | — | Analysis | — |
10-K | Feb 24, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 12, 2026 | — | — | |
8-K | Feb 5, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 11, 2025 | — | — | |
10-Q | Nov 4, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Feb 25, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 5, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Feb 27, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 8, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 8, 2023 | Jun 30, 2023 | — | |
10-Q | May 10, 2023 | Mar 31, 2023 | — | |
10-K | Feb 28, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 7, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 9, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 8, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 10, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest BEAM SEC filings in 2026?
Beam Therapeutics Inc. (BEAM) has filed a 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on March 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did BEAM file its most recent 10-K annual report?
Beam Therapeutics Inc. (BEAM) filed its most recent 10-K annual report on February 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view BEAM 10-Q quarterly reports?
Beam Therapeutics Inc. (BEAM)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every BEAM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has BEAM filed recently?
Beam Therapeutics Inc. (BEAM)'s most recent 8-K was filed on March 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find BEAM insider trading activity (Form 4)?
SignalX aggregates every BEAM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does BEAM file with the SEC?
Beam Therapeutics Inc. (BEAM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new BEAM filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Beam Therapeutics Inc. (BEAM).
What is BEAM's SEC CIK number?
Beam Therapeutics Inc. (BEAM)'s SEC CIK (Central Index Key) number is 1745999. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1745999 to look up all BEAM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find BEAM return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Beam Therapeutics Inc. (BEAM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Beam Therapeutics Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 31+ filings.